Introduction of Comprehensive Pathway Analysis (CPA)

CPA is a biology-driven data analytics platform that provides functional pathway analysis to identify and quantify the cell signaling pathways that drive disease.

Our RNAseq-based platform utilizes FASTQ bulk whole transcriptome RNAseq files or gene expression data to determine signal transduction pathway activity in a quantitative and easy interpretable manner. Using our CPA platform, our partners will be able to study up to a dozen signal transduction pathway activities and analyze potential differences in pathway activity between samples.

This innovative solution aims to provide diagnostic, pharmaceutical, and biopharma partners with enhanced data insights, facilitating faster, more accurate disease drivers that enable the development of targeted therapies and diagnostic tests to improve patient outcomes. InnoSIGN’s CPA offers the first quantifiable analysis of functional pathways across major diseases. Our pathways models were constructed using a biology-driven, holistic approach, looking at relevant target genes, rather than based on data driven knowledge and are designed to be applicable in multiple tissues, providing functional, pan-disease insights.

Enriching existing RNAseq analysis with Insights into Disease Driving Pathway Activity

The goal of CPA is to facilitate a deeper understanding by empowering existing industry players to enrich partner information on top of the existing industry (diagnostic) assays, biopharma and drug development. CPA will provide enhanced insights and thereby allows the healthcare space, and ultimately patients, to combat some of the most challenging diseases of our time.

Leveraging our own existing database containing data from different diseases and tissue types, the potential value of CPA can be explored with various directions of interest.